FDA Grants Fast Track to Rein's LTI-03 for IPF, Interim Data Due H2 2026
RNTX is trading near its 52-week low of $0.694 (11% above the low).
Summary
The FDA granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis, a regulatory milestone that can speed development and review. Rein is already enrolling patients in the Phase 2 RENEW trial, with interim data expected in H2 2026. This follows the company's Q2 2026 report showing $43.6M in cash and a runway into Q1 2028, so the program is funded through the next data readout. Fast Track status adds credibility but does not guarantee approval; the interim data will be the key catalyst for the stock.
At the time of this announcement, RNTX was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.3M. The 52-week trading range was $0.69 to $2.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.